Uniqure N V (QURE)

03:21 AM

UniQure Shares Rise After Mizuho Upgrade - MarketScreener

03:21 AM

09:21 AM

Mizuho Securities Upgrades UniQure NV(QURE.US) to Buy Rating, Announces Target Price $30 - 富途牛牛

09:21 AM

06:21 AM

uniQure stock rating upgraded by Mizuho on Huntington’s disease therapy potential - Investing.com Australia

06:21 AM

Aug 10, 2025

Institutional Ownership Dominates uniQure N.V., Hedge Funds Hold 19% - AInvest

Aug 10, 2025

Aug 10, 2025

uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company - uk.finance.yahoo.com

Aug 10, 2025

Aug 07, 2025

Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest

Aug 07, 2025

Aug 07, 2025

Aberdeen Group Expands Stake in uniQure with Strategic Acquisition - AInvest

Aug 07, 2025

Aug 07, 2025

Aberdeen Group plc Expands Stake in uniQure NV with Strategic Ac - GuruFocus

Aug 07, 2025

Aug 03, 2025

Is uniQure N.V. a good long term investmentGet exclusive access to premium stock research - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What is uniQure N.V. company’s growth strategyStrongest growth potential - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Should I hold or sell uniQure N.V. stock in 2025Unlock daily market insights for better trades - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What makes uniQure N.V. stock price move sharplyBuild a strong portfolio for long-term success - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What drives uniQure N.V. stock priceUnprecedented market success - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Is uniQure N.V. a growth stock or a value stockMaximize returns with disciplined investment techniques - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What is the risk reward ratio of investing in uniQure N.V. stockOutstanding growth strategies - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What are the latest earnings results for uniQure N.V.Discover undervalued stocks before they soar - Jammu Links News

Aug 03, 2025

Aug 03, 2025

How does uniQure N.V. compare to its industry peersMaximize your gains with expert trading tips - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Is uniQure N.V. stock overvalued or undervaluedDiscover high-impact stocks for your portfolio - Jammu Links News

Aug 03, 2025

Aug 02, 2025

What analysts say about uniQure N.V. stockDiscover breakthrough stocks before the crowd - Jammu Links News

Aug 02, 2025

Aug 02, 2025

How strong is uniQure N.V. company’s balance sheetBuild wealth faster with professional insights - Jammu Links News

Aug 02, 2025

Aug 02, 2025

What are the technical indicators suggesting about uniQure N.V.High-octane gains - Jammu Links News

Aug 02, 2025

Aug 01, 2025

Why is uniQure N.V. stock attracting strong analyst attentionEntry Signal Signals To Watch Now - Jammu Links News

Aug 01, 2025

Aug 01, 2025

UniQure N.V. (NASDAQ:QURE) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛

Aug 01, 2025

Aug 01, 2025

A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $35 to $35 - 富途牛牛

Aug 01, 2025

Aug 01, 2025

uniQure Reports Q2 2025 Progress and Financials - TipRanks

Aug 01, 2025

Aug 01, 2025

uniQure’s AMT-130 Gene Therapy for Huntington’s Disease on Track for Q1 2026 BLA Submission After FDA Alignment - Insider Monkey

Aug 01, 2025

Jul 31, 2025

Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com

Jul 31, 2025

Jul 31, 2025

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Zacks Investment Research

Jul 31, 2025

Jul 31, 2025

uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 31, 2025

Jul 31, 2025

RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛

Jul 31, 2025

Jul 30, 2025

uniQure N.V. Earnings Call: Progress Amid Challenges - TipRanks

Jul 30, 2025

Jul 30, 2025

Chardan Capital Analyst Downgrades uniQure Price Target to $35.00, Maintains Buy Rating - AInvest

Jul 30, 2025

Jul 30, 2025

What Caused uniQure’s (QURE.O) Sudden Intraday Surge? - AInvest

Jul 30, 2025

Jul 30, 2025

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga

Jul 30, 2025

Jul 30, 2025

UniQure outlines planned BLA submission for AMT-130 in Q1 2026 amid regulatory alignment and pipeline momentum - MSN

Jul 30, 2025

Jul 30, 2025

UniQure shares rise 9.65% premarket after FDA alignment on AMT-130 statistical analysis plan and CMC requirements. - AInvest

Jul 30, 2025

Jul 30, 2025

UniQure: Q2 Earnings Snapshot - Huron Daily Tribune

Jul 30, 2025

Jul 30, 2025

UniQure shares rise 12.35% premarket after FDA alignment on AMT-130 and positive clinical data. - AInvest

Jul 30, 2025

Jul 30, 2025

Chardan Lowers Price Target on uniQure to $35 From $38, Keeps Buy Rating - MarketScreener

Jul 30, 2025

Jul 30, 2025

uniQure NV (QURE) Q2 2025 Earnings Call Highlights: Navigating R - GuruFocus

Jul 30, 2025

Jul 29, 2025

Chardan Capital maintains Buy rating for uniQure with $35 PT. - AInvest

Jul 29, 2025

Jul 29, 2025

Mizuho Securities Maintains UniQure NV(QURE.US) With Hold Rating - 富途牛牛

Jul 29, 2025